Opinion|Videos|November 29, 2024

Navigating Treatment Options in mCSPC: Choosing the Right Doublet or Triplet Therapy

Key Takeaways

  • Management of mCSPC involves ADT combined with systemic therapies like docetaxel, abiraterone, enzalutamide, or apalutamide.
  • These combination therapies improve overall survival and progression-free survival in mCSPC patients.
SHOW MORE

Panelists discuss how guideline-recommended treatment options for metastatic castration-sensitive prostate cancer (mCSPC) include various combinations of androgen deprivation therapy, docetaxel, and novel hormonal agents, tailored to the patient’s disease characteristics and overall health.

Episodes in this series

Video content above is prompted by the following:

  1. What are the guideline-recommended treatment options for patients with mCSPC (“castration-naive” CSPC)?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
Virtual Event

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

View more
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

View more